- CATALYST home
- Learn about our work
-
See our recent news
- Postdoc stays on task despite COVID-19 shifts
- Web access disparities are a public health issue
- Call for papers: Grand health care challenges
- Study: Privacy fears can lead to withheld info
- OTHC hosted online because of COVID-19
- CATALYST nears inpatient portal study's conclusion
- Dr. Timothy Huerta takes on new role as CRIO
- CATALYST presents infant mortality data visually
- Faculty come together to demo simulation projects
- Postdoc uses big data to solve real-world issues
- Postdoc contributes to patient portal research
- Researchers evaluate care simulation training
- Dr. McAlearney cited in the Washington Post
- CATALYST researchers share work in D.C.
- $2.27M grant awarded to CATALYST’s Dr. Sieck
- Collaboration yields new patient engagement tool
- OSU faculty members write for NEJM Catalyst
- What is T3 research? Dr. Huerta takes a look
- CATALYST researchers publish new work
- Dr. McAlearney speaks in Argentina on SMART
- Council weighs in on major healthcare issues
- Dr. Chandrasekaran to speak at CATALYST
- CATALYST welcomes Dr. Sheon for health IT talk
- Meet our team
- The Center to STOP-COVID
- DataCore
- Join CATALYST
Drs. Gene Oltz, Ann Scheck McAlearney, Ashish Panchal, and Linda Saif will serve as multi-principal investigators for the Center to STOP-COVID, a new Serological Sciences Center of Excellence supported by a five-year, $10 million grant from the National Cancer Institute in the National Institutes of Health. The effort will study the long-term effect of COVID-19 on first responders, health care workers and the general population.
Announcements
Congratulations to Dr. Dan Jones, Professor and Vice Chair of Molecular Pathology at The Ohio State University Wexner Medical Center, who has received a $25,000 Infectious Diseases Institute Interdisciplinary Research Seed Grant as Principal Investigator for "Viral metagenomics to identify shifting SARS-CoV-2 variants and co-occurring respiratory infections in wastewater." For the effort, he will collaborate with Drs. Jiyoung Lee, Vanessa Hale, Matthew Avenarius, Laura Kubatko, Huolin Tu, and Xiaokang Pan.
Recent News

Ohio State to study COVID-19 in first responders with $10 million grant
“Stopping the spread of COVID-19 will require research that cross-cuts basic, translational and applied sciences,” said Dr. Gene Oltz, chair of the Department of Microbial Infection and Immunity at The Ohio State University College of Medicine and lead co-principal investigator for the study, in a news release from Ohio State.
NIH to launch the Serological Sciences Network for COVID-19, announce grant and contract awardees
The National Institutes of Health announced: "The National Cancer Institute (NCI) has launched the Serological Sciences Network for COVID-19 (SeroNet), an initiative aimed at quickly increasing the nation’s antibody testing capacity and engaging the U.S. research community to understand the immune response to COVID-19. NCI is part of the National Institutes of Health." Dr. Ann Scheck McAlearney is pictured.
Emergency medical services personnel awareness and training about personal protective equipment during the COVID-19 pandemic
"With the emergence of the 2019 novel coronavirus disease (COVID-19), appropriate training for emergency medical services (EMS) personnel on personal protective equipment (PPE) is essential," Ashish R. Panchal, pictured, and his co-authors write in Prehospital Emergency Care.
Zooming in on COVID-19: The Infectious Diseases Institute's Virtual COVID-19 Symposium
On December 3, The Ohio State University’s Infectious Diseases Institute hosted a virtual symposium to bring people together to discuss their roles in the response to COVID-19. The IDI “has been really instrumental in bringing these groups together,” said Dr. Linda Saif, pictured.
Eleven Ohio State scientists named AAAS Fellows
Dr. Shan-Lu Liu, professor of veterinary biosciences, was honored "for distinguished contributions to our understanding of virus-host interaction and viral pathogenesis, as well as impact on scientific communication, diversity and international collaboration." Learn more in this story from Ohio State News.
Study finds specific proteins inhibit or enhance virus that causes COVID-19
"Our new findings are potentially quite important because there are people who have mutations in the IFITM3 gene, possibly making them more susceptible not only to influenza but also SARS-CoV-2," said co-author Jacob Yount, an associate professor of Microbial Infection and Immunity and co-director of the Viruses and Emerging Pathogens Program at Ohio State's Infectious Disease Institute, in an article appearing at phys.org.
COVID-19 antibodies on trial
As the initial readouts of trials of antibodies against COVID-19 are released, Nature Biotechnology asked Dr. Linda Saif, pictured, and others in a group of experts "to comment on the challenges and timelines for these products."